Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and immunological studies of measles encephalitis.
Johnson RT, Hirsch RL, Griffin DE, Wolinsky JS, Roedenbeck S, Lindo de Soriano I, Vaisberg A. Johnson RT, et al. Among authors: wolinsky js. Trans Am Neurol Assoc. 1981;106:42-5. Trans Am Neurol Assoc. 1981. PMID: 6184874 No abstract available.
Measles encephalomyelitis--clinical and immunologic studies.
Johnson RT, Griffin DE, Hirsch RL, Wolinsky JS, Roedenbeck S, Lindo de Soriano I, Vaisberg A. Johnson RT, et al. Among authors: wolinsky js. N Engl J Med. 1984 Jan 19;310(3):137-41. doi: 10.1056/NEJM198401193100301. N Engl J Med. 1984. PMID: 6197651
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Among authors: wolinsky js. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, et al. Among authors: wolinsky js. Neurology. 2001 Dec;57(12 Suppl 5):S16-24. Neurology. 2001. PMID: 11902590 No abstract available.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS; Copolymer 1 Multiple Sclerosis Study Group. Johnson KP, et al. Among authors: wolinsky js. Neurology. 2001 Dec;57(12 Suppl 5):S46-53. Neurology. 2001. PMID: 11902595 No abstract available.
305 results